Embecta (Nasdaq:EMBC) today revealed its phased plan to create value and shift priorities toward broader medical applications. The pure-play diabetes technology company has endured ups and downs since its 2022 spin-off from BD. That includes an FDA approval for a disposable insulin patch pump system in September 2024, only to be followed by the discontinuation […]
Auto-injectors
Embecta to undergo further restructuring, lowers guidance amid tariff impact
Embecta (Nasdaq:EMBC) stock was down today after news of restructuring and mixed second-quarter results. Shares of EMBC were down more than 8% to $12.12 apiece near the close of trading today. While the company continues to work through the discontinuation of its insulin patch pump program — the plan for which it says is substantially […]
IDE Group launches ophthalmic auto-injector
IDE Group recently unveiled OKO, its new ophthalmic auto-injector for improving drug delivery precision and efficiency. The company says OKO addresses critical unmet needs in ophthalmology. It aims to improve precision, procedural efficiency and patient safety compared to existing adapted injection methods. Currently, intravitreal injections — essential injections for treating retinal diseases like wet age-related […]
Analysts say Embecta is ‘heading in the right direction’ following patch pump discontinuation
Analysts called a recent stock sell-off at Embecta (Nasdaq:EMBC) “unwarranted” and believe the company is moving in the right direction despite recent challenges. Late last year, Embecta filed with the state of Massachusetts to confirm a workforce reduction affecting 118 employees. This related to the company’s plans to discontinue its insulin patch pump program and restructure. […]
Ypsomed, BD collab on self-injection systems for high-viscosity biologics
BD (NYSE:BDX) and Ypsomed today announced a strategic collaboration to advance self-injection solutions for high-viscosity biologic drugs. In a joint project, the companies pre-assessed and streamlined the integration of the BD Neopak XtraFlow glass prefillable syringe with the Ypsomed YpsoMate 2.25 auto-injector platform. They aim to address current limitations by enabling the delivery of higher-viscosity […]
Ypsomed increases auto-injector production in Germany
Ypsomed announced today that it opened a new production hall at its German site in Schwerin to increase auto-injector production. The Burgdorf, Switzerland-based company said its expansion enables an increase in production capacity to meet growing global demand. CEO Simon Michel also said the company plans to further expand the plant in the coming years. […]
The 9 largest diabetes technology companies in the world
Diabetes technology comes in all shapes and sizes: insulin delivery systems, continuous glucose monitors and more. The companies that develop these technologies come in all shapes and sizes, too. Some focus entirely (or almost entirely) on solutions for people with diabetes. Others are much larger medtech firms that still have sizable business units that focus […]
FDA approves first opioid overdose reversal auto-injector from Purdue Pharma
Purdue Pharma announced that the FDA approved its new drug application (NDA) for the Zurnai (nalmefene injection) auto-injector. The single-dose auto-injector delivers 1.5 mg of nalmefene hydrochloride per actuation. It marks the approved first nalmefene hydrochloride auto-injector for the emergency treatment of known or suspected opioid overdose. The agency approved the first nasal spray formulation […]
Ypsomed closes pen needle, BGM business sale to focus on insulin pump
Ypsomed announced today that it completed the sale of its pen needle and blood glucose monitoring (BGM) businesses to Medical Technology and Devices (MTD). The Burgdorf, Switzerland-based company first announced an agreement to sell off those businesses to MTD in March. Ypsomed plans to support a reliable transition to ensure pen needle supply amid the […]
Ypsomed inks autoinjector deal with German pharma company Medac
Ypsomed announced that German company Medac selected its autoinjector technology for the relaunch of its methotrexate pen. The YpsoMate 1.0 will gradually replace the current available metoject/metex pen for the German company’s methotrexate products. Ypsomed launched its new autoinjector in various countries during the first quarter of this year. Medac develops subcutaneous methotrexate (MTX) products, […]
